Anaptysbio Inc Stock Price, News & Analysis

AnaptysBio (ANAB) announced positive 6-month data for rosnilimab in Phase 2b trial for moderate-to-severe rheumatoid arthritis. The drug demonstrated JAK-like efficacy with monthly dosing, achieving significant improvements in disease activity measures. The 424-patient trial showed 69% of patients achieved low disease activity (LDA) across all doses at Week 14, with responses lasting at least 2 months after treatment. The drug showed favorable safety with no treatment-related serious adverse events. In b/tsDMARD-naive patients, LDA rates reached up to 72% at Week 28, while b/tsDMARD-experienced patients showed up to 56% LDA. The drug demonstrated ~50% reduction in CRP levels and ~90% reduction in PD-1high T cells, indicating strong anti-inflammatory effects. Rosnilimab targets the ~$20 billion U.S. RA market, with potential for extended dosing intervals during maintenance treatment.

AnaptysBio (NASDAQ: ANAB) has announced it will host an investor call and webcast on June 3, 2025 to present updated data from its global Phase 2b RENOIR clinical trial. The trial evaluates rosnilimab, a PD-1+ T cells depleter and agonist, for treating moderate-to-severe rheumatoid arthritis.

The presentation will feature distinguished speakers including Paul Emery, M.D. from the University of Leeds and Jonathan Graf, M.D. from UCSF. Following the data release, company executives led by CEO Daniel Faga will participate in two major investor conferences: the Jefferies Global Healthcare Conference on June 5 and the Goldman Sachs Global Healthcare Conference on June 11, 2025.

AnaptysBio (NASDAQ: ANAB) reported Q1 2025 financial results and provided key business updates. The company's lead program rosnilimab achieved positive Phase 2b results in rheumatoid arthritis, with upcoming data presentation in June. A Phase 2 trial for ulcerative colitis is ongoing with initial data expected in Q4 2025. The company has $383.0 million in cash as of March 31, 2025, with runway through 2027. Q1 financial highlights include collaboration revenue of $27.8 million (up from $7.2M in Q1 2024) and a net loss of $39.3 million ($1.28 per share). AnaptysBio authorized a $75 million stock repurchase program in March 2025. The company continues to advance its pipeline, including Phase 1a trials for ANB033 and ANB101, while benefiting from its GSK collaboration, which generates substantial royalties from Jemperli sales ($220M in Q1 2025).

AnaptysBio (ANAB) has announced a $75 million Stock Repurchase Plan authorized by its Board of Directors. The clinical-stage biotechnology company maintains a strong financial position with over $420 million in cash, cash equivalents, and investments as of December 31, 2024.

The company expects to receive a $75 million commercial sales milestone payment from GSK in 2025 or 2026. Despite the potential full execution of the buyback plan, AnaptysBio reaffirms its cash runway guidance through year-end 2027 for its R&D plan, excluding future royalties from its GSK immuno-oncology collaboration.

The stock repurchase program will run through December 31, 2025, with shares to be bought in open market transactions under Rules 10b5-1 and 10b-18. The company maintains flexibility to suspend or discontinue the program at any time.

AnaptysBio (ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, has announced its participation in three major investor conferences in March 2025. The company's leadership, including President and CEO Daniel Faga, will attend:

• TD Cowen 45th Annual Healthcare Conference in Boston (March 4)
• Leerink Partners 2025 Global Healthcare Conference in Miami (March 11)
• Barclays 27th Annual Global Healthcare Conference in Miami (March 12)

The events will feature fireside chats, presentations, and one-on-one investor meetings. Live webcasts will be available on the company's investor relations website, with replays accessible for 30 days post-events.

AnaptysBio (NASDAQ: ANAB) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its immunology therapeutics pipeline. The company's lead drug rosnilimab achieved positive Phase 2b results in rheumatoid arthritis, demonstrating the highest-ever reported CDAI LDA response over 6 months. The trial showed 69% of rosnilimab-treated patients achieved CDAI LDA at Week 14.

Financial highlights include year-end cash and investments of $420.8 million, with runway extended through 2027. Full-year 2024 collaboration revenue increased to $91.3 million from $17.2 million in 2023. The company reported a net loss of $145.2 million for 2024, or $5.12 per share.

Key pipeline updates include accelerated top-line Phase 2 data for rosnilimab in ulcerative colitis expected in Q4 2025, ongoing Phase 1a trials for ANB033, and planned initiation of ANB101 Phase 1a trial. Additionally, AnaptysBio announced a global license agreement with Vanda Pharmaceuticals for imsidolimab development.

AnaptysBio (NASDAQ: ANAB) announced significant positive results from its Phase 2b RENOIR trial of rosnilimab for moderate-to-severe rheumatoid arthritis (RA). The 424-patient global trial achieved its primary endpoint with statistical significance across all rosnilimab doses versus placebo at Week 12.

Key highlights include:

• 69% of rosnilimab-treated patients achieved CDAI low disease activity at Week 14
• Demonstrated highest ever reported responses on key secondary endpoints
• Showed sustained efficacy through Week 28
• Safe and well-tolerated with adverse event rates similar to placebo

The trial evaluated three dosing regimens: 100mg every four weeks, 400mg every four weeks, and 600mg every two weeks. The drug showed robust pharmacological activity with ~90% reduction in PD-1high T cells and ~50% reduction in CRP levels. Full Week 28 data expected in Q2 2025, with Phase 2 ulcerative colitis data anticipated in Q4 2025.

AnaptysBio (ANAB) has announced it will host an investor call and live webcast on February 12, 2025, at 8:30 AM ET to present top-line data from its global Phase 2b RENOIR clinical trial. The trial evaluates rosnilimab, a PD-1+ T cells depleter and agonist, for the treatment of moderate-to-severe rheumatoid arthritis. The data will be released through a morning press release and discussed during the webcast, which will be accessible via the company's investor relations website. A replay will remain available for at least 30 days after the event.

AnaptysBio (NASDAQ: ANAB), a clinical-stage biotechnology company specializing in innovative immunology therapeutics, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. Daniel Faga, the company's president and chief executive officer, will deliver a presentation on Wednesday, February 5, 2025, at 1:00 PM ET / 10:00 AM PT.

Interested parties can access a live webcast of the presentation through the investor section of the Anaptys website at http://ir.anaptysbio.com/events. The presentation recording will remain available for replay for a minimum of 30 days after the event.